Europe approves KEYTRUDA® as first-line therapy in certain colorectal cancers
The European Commission approval makes KEYTRUDA® (pembrolizumab) the first anti-PD-1…
The European Commission approval makes KEYTRUDA® (pembrolizumab) the first anti-PD-1 therapy approved for metastatic microsatellite instability-high (MSI-H) colorectal cancer patients in Europe.